Literature DB >> 34964500

Omicron and S-gene target failure cases in the highest COVID-19 case rate region in Canada-December 2021.

Anthony Li1,2, Allison Maier1, Megan Carter1,3, Tianxiu Hugh Guan1,4,5.   

Abstract

Entities:  

Keywords:  COVID-19; Omicron; SARS-CoV-2; pandemic; public health; variants of concern

Mesh:

Year:  2022        PMID: 34964500      PMCID: PMC9015418          DOI: 10.1002/jmv.27562

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


× No keyword cloud information.
As the newly detected SARS‐CoV‐2 B.1.1.529 variant (Omicron) rapidly spreads worldwide, the Kingston, Frontenac, Lennox & Addington (KFL&A) region has had record‐setting COVID‐19 case numbers, with 1574 active cases as of December 21, 2021—a higher case rate than any other region in Canada (Figure 1).
Figure 1

Epidemic curve for active COVID‐19 cases in the Kingston, Frontenac, Lennox & Addington Region by case rate, November–December 2021. Variant rate estimated to include confirmed, suspect, and likely cases. Confirmed cases have had full genetic sequencing. Suspect cases have lab results consistent with SARS‐CoV‐2 S gene target failure. Likely cases have been linked to other confirmed, suspect or other likely Omicron cases through exposures

Epidemic curve for active COVID‐19 cases in the Kingston, Frontenac, Lennox & Addington Region by case rate, November–December 2021. Variant rate estimated to include confirmed, suspect, and likely cases. Confirmed cases have had full genetic sequencing. Suspect cases have lab results consistent with SARS‐CoV‐2 S gene target failure. Likely cases have been linked to other confirmed, suspect or other likely Omicron cases through exposures The Omicron variant was classified as a variant of concern by the World Health Organization on November 26, 2021. One of its 50+ mutations reduces PCR amplification of the S gene, allowing for S gene target failure (SGTF) to be used as an Omicron marker while awaiting sequencing. The rate of detection of Omicron has been faster than other strains in previous pandemic waves, suggesting Omicron may have the ability for faster growth. From December 3, the detection of the first case of Omicron in the KFL&A region, until December 21, 2021, there have been 1063 Omicron cases that were either confirmed or suspected.* A total of 59% of these cases were 18–24 years old while 27% were 25–39 years old. This has corresponded with the main outbreak environments being in Postsecondary education (N = 64) and food and beverage settings (N = 106), with considerable overlap between these settings. There have only been three cases in the 70+ age group and no hospitalizations. There have been no deaths to‐date in KFL&A due to Omicron. Initial modeling estimates have placed the R for Omicron in KFL&A at 1.5 (90% credible interval: 0.78–2.34; modeling estimates conducted with R and the EpiNow2 package). In confirmed and suspect Omicron cases, 9.6% were asymptomatic. For symptomatic cases, the most common symptoms reported were nasal congestion (73%), cough (65%), headaches (54%), sore throat (48%). Of note, only 10% reported shortness of breath. Frequencies of symptom combinations between any two symptoms are displayed in Figure 2.
Figure 2

Symptom combinations between any two symptoms in cases with more than one symptom documented at any point. The most common combination of any two symptoms in cases with two or more symptoms were: cough and nasal congestion (63%), headache and nasal congestion (51%), cough and headache (48%), nasal congestion and sore throat (47%), and cough and sore throat (44%)

Symptom combinations between any two symptoms in cases with more than one symptom documented at any point. The most common combination of any two symptoms in cases with two or more symptoms were: cough and nasal congestion (63%), headache and nasal congestion (51%), cough and headache (48%), nasal congestion and sore throat (47%), and cough and sore throat (44%) Outside of 45 individuals not yet old enough to be double‐vaccinated, 31 cases were unvaccinated, 19 cases were partially vaccinated,† and 64 cases had unknown vaccination status. The remainder of cases were at least double‐vaccinated.‡ There was a median of 22 weeks between second dose and symptom onset. There were also 13 Omicron cases in individuals with a third dose: four received their booster 32–35 days before onset, two received theirs 15 days before onset, and seven cases received their booster <14 days before onset. There have been 12 confirmed reinfections with Omicron; all were symptomatic and double‐vaccinated.§ These cases had a mix between suspect wild‐type, alpha, and delta variants at first infection. Given the rapid propagation of the Omicron variant as well as the incidence of immune escape in double‐vaccinated individuals, everyone must continue to remain cautious and vigilant in a time of rapid case surge. This includes physical distancing, limiting nonessential travel and gatherings, proper respiratory and hand hygiene, robust personal protective equipment, and adhering to testing and isolation requirements based on symptoms. Getting a booster vaccine, as able, may be an effective way to prevent breakthrough infections. Postsecondary education institutions and food and beverage settings remain high‐risk transmission environments most likely due to reduced physical distancing and higher frequency of unmasking behavior. Strong collaboration and communication between public officials and citizens are needed to ensure a unified approach to mitigating community spread.

CONFLICT OF INTERESTS

The authors declare there are no conflict of interests. The authors alone are responsible for the content and writing of the article.
  2 in total

1.  PCR performance in the SARS-CoV-2 Omicron variant of concern?

Authors:  César M J A Metzger; Reto Lienhard; Helena M B Seth-Smith; Tim Roloff; Fanny Wegner; Jonas Sieber; Michael Bel; Gilbert Greub; Adrian Egli
Journal:  Swiss Med Wkly       Date:  2021-12-10       Impact factor: 2.193

2.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.

Authors:  Salim S Abdool Karim; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2021-12-03       Impact factor: 202.731

  2 in total
  18 in total

1.  Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice.

Authors:  Irene González-Domínguez; Jose Luis Martínez; Stefan Slamanig; Nicholas Lemus; Yonghong Liu; Tsoi Ying Lai; Juan Manuel Carreño; Gagandeep Singh A; Gagandeep Singh B; Michael Schotsaert; Ignacio Mena; Stephen McCroskery; Lynda Coughlan; Florian Krammer; Adolfo García-Sastre; Peter Palese; Weina Sun
Journal:  bioRxiv       Date:  2022-03-22

2.  Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.

Authors:  Irene González-Domínguez; Jose Luis Martínez; Stefan Slamanig; Nicholas Lemus; Yonghong Liu; Tsoi Ying Lai; Juan Manuel Carreño; Gagandeep Singh; Gagandeep Singh; Michael Schotsaert; Ignacio Mena; Stephen McCroskery; Lynda Coughlan; Florian Krammer; Adolfo García-Sastre; Peter Palese; Weina Sun
Journal:  Microbiol Spectr       Date:  2022-06-06

Review 3.  Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures.

Authors:  Wenxia Shao; Weiying Zhang; Xiang Fang; Daojun Yu; Xianjun Wang
Journal:  J Microbiol Immunol Infect       Date:  2022-04-26       Impact factor: 10.273

Review 4.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Authors:  Rekha Khandia; Shailja Singhal; Taha Alqahtani; Mohammad Amjad Kamal; Nahed A El-Shall; Firzan Nainu; Perumal Arumugam Desingu; Kuldeep Dhama
Journal:  Environ Res       Date:  2022-01-29       Impact factor: 8.431

5.  [Reinfection by the Omicron variant in patients previously infected with the Delta variant of the SARS-CoV-2 coronavirus: An increasingly frequent reality in Primary Care].

Authors:  N Sánchez-Varela; S Cinza-Sanjurjo; M Portela-Romero
Journal:  Semergen       Date:  2022-01-14

Review 6.  Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.

Authors:  Giorgio Tiecco; Samuele Storti; Melania Degli Antoni; Emanuele Focà; Francesco Castelli; Eugenia Quiros-Roldan
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

7.  Influence of immune escape and nasopharyngeal virus load on the spread of SARS-CoV-2 Omicron variant.

Authors:  Marion Migueres; Chloé Dimeglio; Pauline Trémeaux; Florence Abravanel; Stéphanie Raymond; Sébastien Lhomme; Jean-Michel Mansuy; Jacques Izopet
Journal:  J Infect       Date:  2022-02-07       Impact factor: 38.637

8.  Effects of vaccination, new SARS-CoV-2 variants and reinfections on post-COVID-19 complications.

Authors:  Mária Orendáčová; Eugen Kvašňák
Journal:  Front Public Health       Date:  2022-07-29

9.  The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data.

Authors:  Abbas Khan; Hira Waris; Memoona Rafique; Muhammad Suleman; Anwar Mohammad; Syed Shujait Ali; Taimoor Khan; Yasir Waheed; Chenguang Liao; Dong-Qing Wei
Journal:  Int J Biol Macromol       Date:  2022-01-19       Impact factor: 6.953

10.  Clinical Evaluation of a Fully-Automated High-Throughput Multiplex Screening-Assay to Detect and Differentiate the SARS-CoV-2 B.1.1.529 (Omicron) and B.1.617.2 (Delta) Lineage Variants.

Authors:  Dominik Nörz; Moritz Grunwald; Hui Ting Tang; Celine Weinschenk; Thomas Günther; Alexis Robitaille; Katja Giersch; Nicole Fischer; Adam Grundhoff; Martin Aepfelbacher; Susanne Pfefferle; Marc Lütgehetmann
Journal:  Viruses       Date:  2022-03-15       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.